Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include FirstWord Pharma, Endpoints News, Business Wire and BioPharma Dive. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 67d ago.
Quick answers
Why is "Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdo" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- Takeda's oral TYK2 zasocitinib tops Sotyktu in Phase III showdown FirstWord Pharma · 91d ago
- Takeda’s plaque psoriasis pill beats Bristol Myers’ Sotyktu in Phase 3 Endpoints News · 91d ago
- Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations Business Wire · 91d ago
- Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test BioPharma Dive · 91d ago
- Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown Fierce Biotech · 91d ago
Topics
Related trends
A New Drug Lifts the Fog of Sleepiness for Those With Narcolepsy
Takeda has released Phase 3 study data for oveporexton, a new drug designed to treat the excessive daytime sleepiness associated with narcolepsy.
A ‘Transformative’ Narcolepsy Drug Opens New Opportunities in Neuroscience
The pharmaceutical company Takeda has released Phase 3 data for oveporexton, a transformative drug targeting narcolepsy type 1 symptoms.
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Novartis and Bristol Myers Squibb halt autoimmune CAR-T trials following patient deaths, impacting the sector.
7 new dementia risk factors revealed
New medical guidance identifies seven additional risk factors for dementia, highlighting a significant gap in public awareness among adults over 40.
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Novartis and Bristol Myers Squibb halt multiple CAR-T clinical trials for autoimmune diseases following patient deaths and safety reviews.
Seahawks Droppings: Jason Myers meltdown cements Seattle’s winless preseason
Seattle Seahawks kicker Jason Myers missed a final-play field goal, leaving the team winless after a 9-9 preseason tie with the Kansas City Chiefs.